They described the tumor-suppressive effects of doxorubicin on p53-dependent induction of IFNλIFN-related genes, which is consistent with our demonstration that effective p53 elevation boosts doxorubicin to repress breast cancer cell survival. Here, TP53 is linked to neoplasm.